Antipsychotics

Articles filed under Antipsychotics. Part of CNS drugs.

• New Depot Antipsychotics

  January 31, 2016

  New long-acting (depot) antipsychotics were approved in 2015: Aristada and Invega Trinza. This practical guide from the Psychopharmacology Institute summarizes the essentials for prescribers. Long-Acting Injectable Antipsychotics: A Practical Guide for Prescribers 1 Advantages and disadvantages of long-acting antipsychotics 1.1 Potential advantages 1.2 Potential disadvantages 2 Clinical questions answered 3 Tables summarizing individual agents 3.1

• Glutamate receptors

  January 9, 2011

  Overview of ionotropic (NMDA, AMPA, Kainate) and metabotropic glutamate receptors (mGluR).

• Caution on olanzapine in adolescents

  October 22, 2010

  Caution on olanzapine in adolescents

• MCQs for USMLE review on psychopharmacology: antipsychotics, benzodiazepines, antidepressants and lithium

  March 1, 2009

  These pharmacology MCQs from the UMKC School of Medicine have a different degree of difficulty, but are useful to review pharmacology of psychotropics. Psychotropics Item Number: 11667 correct answer: 4 category: Psychotropics 1. The symptoms of tardive dyskinesia will acutely improve with: 1. administration of diphenhydramine 2. administration of amantadine 3. administration of bromocriptine 4.

• Quetiapine extended release tablets (Seroquel XR): efficacy, tolerability and adherence.

  December 24, 2008

  Information about quetiapine extended release tablets, from the National Prescribing Service RADAR “There is no evidence that extended-release tablets improve efficacy, tolerability or adherence Once-daily dosing with quetiapine extended-release tablets is equivalent to twice-daily dosing with quetiapine immediate-release tablets, e.g. quetiapine extended release 600 mg once daily is equivalent to quetiapine immediate release 300 mg

• Risk of death in patients with dementia that use typical antipsychotics: EMEA’s press release

  November 28, 2008

  Questions and answers on the review of the use of conventional antipsychotic medicines in elderly patients with dementia The European Medicines Agency (EMEA) has completed a review of the evidence available on the safety of conventional antipsychotic medicines in elderly patients with dementia. The Agency’s Committee for Medicinal Products for Human Use (CHMP) has concluded that there